Skip to main content
. 2020 Nov 5;85:153404. doi: 10.1016/j.phymed.2020.153404

Table 3.

The primary outcome of the groups.

Total Control group CHM group p
Clinical improvement* N = 86 N = 43 N = 43 0.518
No improvement, No. (%) 44 (51%) 20 (47%) 24 (56%)
Improvement, No. (%) 42 (49%) 23 (54%) 19 (44%)
Disease improvement or deterioration N = 86 N = 43 N = 43 0.437
Improvement, No. (%) 53 (62%) 25 (58%) 28 (65%)
Non-improvement, No. (%) 18 (21%) 9 (21%) 9 (21%)
Worse, No. (%) 15 (17%) 9 (21%) 6 (14%)
Score on six-category scale on Day 28 N = 86 N = 43 N = 43 0.775
6. Death, No. (%) 11 (13%) 9 (21%) 2 (5%)
5. Hospitalization, requiring ECMO, invasive mechanical ventilation, or both, No. (%) 1 (1%) 0 (0%) 1 (2%)
4. Hospitalization, requiring HFNC or non-invasive mechanical ventilation, No. (%) 2 (2%) 1 (2%) 1 (2%)
3. Hospitalization, requiring supplemental oxygen, No. (%) 23 (27%) 9 (21%) 14 (33%)
2. Hospitalization, not requiring supplemental oxygen, No. (%) 4 (5%) 0 (0%) 4 (9%)
1. Discharge from hospital, No. (%) 45 (52%) 24 (56%) 21 (49%)

* Clinical improvement was defined as a decline of two categories on the modified six-category ordinal scale of clinical status or hospital discharge.

The disease improvement or deterioration was defined as at least one-category increase or decrease on the six-category scale.

The chi-squared test was used to analyze the six-category scale on Day 28, and the results showed no statistical significance.

The clinical improvement of the two groups on Day 28 were classified as one-way ordered data (grouping variable disorder, response variable ordering). The nonparametric test, Wilcoxon rank sum test showed no significant difference.

The disease improvement or deterioration on Day 28 and mortality rates were two-way disordered data. The chi-squared test showed no significant difference.